APGE实时信号 | 通过Getagraph.com最大化利润

购买 136716 min ago

@ $35.28

发出时间: 15 Feb 2024 @ 04:02

回报率: 42.60%

上一信号: Feb 14 - 01:37

上一信号: 出售

回报率: 0.28 %

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Stats
今日成交量	379 725
平均成交量	711 880
市值	2.94B
EPS	$0 ( 2024-03-11 )
下一个收益日期	( $-0.600 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0850 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-29	Fairmount Funds Management Llc	Buy	51 166	Common Stock
2024-01-29	Fairmount Funds Management Llc	Sell	892 529	Common Stock
2023-12-18	Henderson Michael Thomas	Buy	398 512	Stock Option (Right to Buy)
2023-07-13	Fairmount Funds Management Llc	Buy	1 992 734	Common Stock
2023-07-13	Fairmount Funds Management Llc	Buy	892 529	Common Stock

INSIDER POWER
47.02
Last 9 transactions
Buy: 3 438 612 \| Sell: 892 529

音量相关性

長: -0.38 (neutral)

短: -0.67 (moderate negative)

Signal:(42.984) Neutral

Apogee Therapeutics, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Apogee Therapeutics, Inc. 相关性 - 货币/商品

-0.78
( moderate negative )

-0.67
( moderate negative )

-0.78
( moderate negative )

-0.71
( moderate negative )

-0.73
( moderate negative )

0.72
( moderate )

Apogee Therapeutics, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.660

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-1.660

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.790

Financial Reports:

No articles found.

Apogee Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.